ASH: Glofitamab Aids Relapsed, Refractory Diffuse Large B-Cell Lymphoma
39 percent of patients had a complete response, with median time to complete response of 42 days
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.